Baidu
map

CHEST:镇咳药对慢性咳嗽患者呼吸中枢的影响

2017-02-15 MedSci MedSci原创

咳嗽是由与呼吸节律生成相关的神经元池产生的,在中心水平发挥作用的镇咳药物例如阿片样物质可以抑制通气。左羟丙哌嗪是作用在气道感觉神经水平的非阿片样外周镇咳药物。但是,左羟丙哌嗪对中枢不发挥作用还有待进一步确定。近期,一项发表在杂志CHEST上的研究旨在比较左羟丙哌嗪和阿片类镇咳药二氢可待因对慢性咳嗽患者常规二氧化碳再呼吸试验的呼吸反应的影响。此项研究收集了24名门诊慢性咳嗽患者(年龄39-70岁)。

咳嗽是由与呼吸节律生成相关的神经元池产生的,在中心水平发挥作用的镇咳药物例如阿片样物质可以抑制通气。左羟丙哌嗪是作用在气道感觉神经水平的非阿片样外周镇咳药物。


但是,左羟丙哌嗪对中枢不发挥作用还有待进一步确定。

近期,一项发表在杂志CHEST上的研究旨在比较左羟丙哌嗪和阿片类镇咳药二氢可待因对慢性咳嗽患者常规二氧化碳再呼吸试验的呼吸反应的影响。

此项研究收集了24名门诊慢性咳嗽患者(年龄39-70岁)。在单独的试验中,每个患者随机使用60mg左羟丙哌嗪,或15mg双氢可待因或匹配的安慰剂。随后,患者呼吸5分钟,93%氧气和7%CO 2的混合物。连续监测分数呼吸末CO2(FETCO2)和吸气分钟通气量(VI)。还评估了呼吸模式变量的变化。

结果显示:与二氢可待因不同,左羟丙哌嗪和安慰剂不影响对高碳酸血症的呼吸反应(P <0.01)。高碳酸血症的通气增加主要是由呼吸模式的体积分量的增加引起的。

此项研究结果与左羟丙哌嗪的外周作用一致;评估通气对CO2的反应可能是调查镇咳药对中枢呼吸作用的有用工具。

原始出处:
Mannini C, Lavorini F, Zanasi A, et al. A Randomised Clinical Trial Comparing the Effects of Antitussives on Respiratory Centre Output in Patients with Chronic Cough. Chest. 2017 Feb 10. pii: S0012-3692(17)30171-X. doi: 10.1016/j.chest.2017.02.001.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929283, encodeId=1a8c19292834e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Dec 12 18:40:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050596, encodeId=110e205059654, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Sep 26 06:40:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176422, encodeId=a8cf1e642273, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Feb 16 10:14:28 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176414, encodeId=a8b01e6414da, content=很好!辛苦编辑!学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170207/IMG589913E36908D4741.jpg, createdBy=99331680071, createdName=knowheart, createdTime=Thu Feb 16 09:49:27 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-12-12 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929283, encodeId=1a8c19292834e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Dec 12 18:40:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050596, encodeId=110e205059654, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Sep 26 06:40:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176422, encodeId=a8cf1e642273, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Feb 16 10:14:28 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176414, encodeId=a8b01e6414da, content=很好!辛苦编辑!学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170207/IMG589913E36908D4741.jpg, createdBy=99331680071, createdName=knowheart, createdTime=Thu Feb 16 09:49:27 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929283, encodeId=1a8c19292834e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Dec 12 18:40:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050596, encodeId=110e205059654, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Sep 26 06:40:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176422, encodeId=a8cf1e642273, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Feb 16 10:14:28 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176414, encodeId=a8b01e6414da, content=很好!辛苦编辑!学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170207/IMG589913E36908D4741.jpg, createdBy=99331680071, createdName=knowheart, createdTime=Thu Feb 16 09:49:27 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-02-16 1e10c84am36(暂无匿称)

    文章真心不错耶

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1929283, encodeId=1a8c19292834e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Dec 12 18:40:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050596, encodeId=110e205059654, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Sep 26 06:40:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176422, encodeId=a8cf1e642273, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Feb 16 10:14:28 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176414, encodeId=a8b01e6414da, content=很好!辛苦编辑!学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170207/IMG589913E36908D4741.jpg, createdBy=99331680071, createdName=knowheart, createdTime=Thu Feb 16 09:49:27 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-02-16 knowheart

    很好!辛苦编辑!学习了谢谢分享

    0

相关资讯

FDA黑框警告:这两类药混吃要小心

导语:阿片类止痛或镇咳药与苯二氮卓类药物混吃要小心。FDA于8月31日发出黑框警告,强烈建议阿片类药物不要与苯二氮卓类或其他抑制中枢神经系统的药物混合服用,以免造成严重不良反应,包括呼吸困难甚至死亡。FDA要求修订阿片类和苯二氮卓类药物的药品标签及用药指导,具体包括黑框警告、警告及注意事项、适应症和用法、患者咨询信息等部分。FDA还表示,将会继续评估阿片类成瘾及戒断的辅助治疗药物,与苯二氮卓类药物

Baidu
map
Baidu
map
Baidu
map